ATCC®

CRISPR/Cas9-Engineered 3D Tissue Culture Models of Drug-Resistant Melanoma

CRISPR/Cas9 genome-editing technology is a powerful new tool for developing cell-based models with disease-relevant mutations. In this presentation, we describe how this advanced technology was used to introduce specific point mutation that confers drug resistance into the A375 melanoma line to create the MEK1 Q56P Mutant-A375 Isogenic Cell Line. The new isogenic cell line is resistant to both MEK and BRAF inhibitors and, like the current isogenic KRAS and NRAS Mutant-A375 Cell Lines, sensitive to combination therapies targeting both upstream and downstream elements of the Ras/Raf-MAPK signaling pathway, making it an ideal model for screening and evaluating novel therapeutics and combination treatments targeting multidrug-resistant melanomas.

*
*
*
*
*
*